GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Guardant Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$157.88−0.72 (-0.45%)
Close on Oct 19, 2026
- Market cap
- $20.98B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
64.5%
Operating margin
-44.5%+44.4 pts over 5 years
Net margin
-42.4%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +32.9% | +29.8% | +27.9% | – | |
| Gross profit | +40.9% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 348.4% | |
| Return on assets | – | – | -23.8% | |
| Current ratio | – | 28.27 | 4.84 | |
| Interest coverage | -14.5× | -53.5× | -112.2× | |
| Inventory turnover | – | – | 4.4× | |
| Capex to revenue | 7.0% | 12.6% | 4.9% | |
| Diluted shares | 13M | 98M | 125M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Guardant Health generated $1.27B from operations and spent $301.38M on capital expenditure, dividends and share buybacks. 85% of that went back into the business.
Generated
$1.27B
Used
$301.38M
Capital expenditure$256.37M85%Dividends$00%Share buybacks$45.01M15%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-42.4%
×Asset turnover0.56×
×Equity multiplier-14.64×
=Return on equity, FY2025348.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -42.4% | 0.56× | -14.64× | 348.4% |
| FY2024 | -59.0% | 0.45× | 171.88× | -4584.5% |
| FY2023 | -85.0% | 0.33× | 15.52× | -438.1% |
| FY2022 | -145.6% | 0.24× | 5.41× | -185.7% |
| FY2021 | -103.0% | 0.17× | 2.30× | -39.6% |
| FY2019 | -35.3% | 0.28× | 1.21× | -11.8% |
| FY2018 | -93.8% | 0.19× | 1.18× | -21.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$416.28M
- Cash generatingOperating cash flow above zero-$184.76M
- Return on assets improvedROA up on the prior year-24.4% → -28.0%
- Earnings backed by cashOperating cash flow above net income-$184.76M vs -$416.28M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.68 → 4.84
- No dilutionShare count did not rise123M → 125M
- Gross margin improvedGross margin up on the prior year60.79% → 64.46%
- More efficientAsset turnover rose0.41 → 0.66